Fortrea Holdings Inc. (FTRE)

In December 2025, Fortrea's shares surged by 27%, but were still down 34% over the past year. In December 2024, the stock soared 10% due to reports of the company canceling from some sell-side conferences, following activist investor Corvex Management disclosing a stake. In November 2025, Fortrea reported third-quarter results and raised its 2025 revenue guidance. In August 2025, Anshul Thakral joined as the new CEO. In July 2025, a class-action lawsuit was filed against Fortrea and its executives for potential violations of federal securities laws. In January 2026, Fortrea shares traded up, driven by an analyst upgrade from Evercore ISI Group.

Information explicitly detailing the demand seasonality for Fortrea Holdings, Inc.'s products and services is not available. Demand for its services is generally driven by the research and development (R&D) spending of pharmaceutical, biotechnology, and medical device companies. Factors such as robust global demand, favorable demographic trends, and increased R&D create long-term growth opportunities for the industry.

Fortrea Holdings, Inc. (FTRE) is a global contract research organization (CRO) providing clinical development solutions to the life sciences industry, operating within the Healthcare sector, specifically in Biotechnology and Medical Research. Fortrea offers biopharmaceutical product and medical device development services to pharmaceutical, biotechnology, and medical device customers worldwide, spanning the entire clinical development spectrum, from Phase I through Phase IV clinical trial management. The company was formed in 2023 as an independent, publicly traded company after being spun off from Labcorp's clinical development business.

Fortrea Holdings Inc. has a global presence with primary office locations in the United States, the United Kingdom, China, India, and Singapore. The company conducts operations in over 90 countries worldwide, with approximately 14,500 to 19,000 employees globally.

Fortrea's brand reputation has been impacted by a securities fraud class-action lawsuit initiated in July 2025, stemming from allegations of overstated cost savings and margin improvements. Concerns have been raised about the company's business model, flat sales, lack of profitability, and significant debt, leading to investigations into whether Fortrea accurately disclosed its financial condition and risks.

Approximately 75.02% to 103.46% of Fortrea's stock is held by institutional investors, 0.52% to 0.54% by insiders, and 24.45% by retail investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Goldman Sachs Group Inc.